DSM-Firmenich stock enters exclusive US sunscreen window
Published on 11/11/2026 at 18:23 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSNew sunscreen market takes shape
- FDA approval opened the US market for bemotrizinol after more than two decades without a new active sunscreen filter.
- Ultra Violette and Neutrogena have launched early products, while broader adoption depends on customer rollouts and regulatory listings.
- The exclusive supply window gives DSM-Firmenich a potential beauty-care sales driver but leaves execution and post-exclusivity risks.
DSM-Firmenich is entering a newly opened US sunscreen market as its bemotrizinol ingredient reaches consumers. The development gives the Swiss-Dutch group a defined commercial window in beauty care, although sales momentum will depend on customer launches.
On October 15, 2026, Latin Times reported that the US Food and Drug Administration had added bemotrizinol, also known as BEMT, to the over-the-counter sunscreen monograph on June 9. Sales were permitted from August 9, making BEMT the first new active sunscreen filter added to the US monograph since 1999.
Exclusive supply window opens
DSM-Firmenich supplies BEMT under the Parsol Shield brand and holds 18 months of exclusive US marketing rights, according to the report. The period began with the first commercial launch, creating a temporary position as the central supplier for products using the ingredient.
Ultra Violette launched its Unblock Screen SPF 50 at Sephora on August 31, followed by Neutrogena products listed online from September 17. BEMT offers broad-spectrum UVA and UVB protection in one chemical filter and is permitted at concentrations of up to 6 percent under the FDA framework.
Launch pace is the next test
For investors, the key indicators are the number and timing of additional brand launches, consumer uptake and the contribution to DSM-Firmenich's beauty-related sales. Wider availability requires manufacturers to complete formulation, labeling and over-the-counter listing requirements.
DSM-Firmenich stock traded at 106.30 euros on Lang & Schwarz at 18:16 CET on Wednesday, November 11, 2026.
DSM-Firmenich stock at a glance
- Company: DSM-Firmenich
- ISIN: CH1216478797
- Trading venue: Lang & Schwarz
- Price: 106.30 euros at 18:16 CET on November 11, 2026
European chemicals and consumer-goods shares remain an important backdrop for investors, with the SMI among the regional reference indexes.
More news and analyses on DSM-Firmenich stock will track US product launches, customer adoption and the development of BEMT-related demand.
